Cipher Mining
CIFR
TeraWulf
WULF
BTCS Inc
BTCS
Riot Platforms
RIOT
Hut 8
HUT
US Stock MarketDetailed Quotes
CRVO CervoMed
- 2.280
- +0.010+0.44%
Trading Jan 24 12:18 ET
18.82MMarket Cap-1.58P/E (TTM)
2.350High2.250Low43.33KVolume2.270Open2.270Pre Close99.51KTurnover0.96%Turnover RatioLossP/E (Static)8.25MShares26.37952wk High0.41P/B10.33MFloat Cap1.80052wk Low--Dividend TTM4.53MShs Float3375000000.000Historical High--Div YieldTTM4.41%Amplitude1.800Historical Low2.296Avg Price1Lot Size
Trending Stocks
U.S. Crypto Concept Stocks U.S. Crypto Concept Stocks
Companies involved in the creation, trade, and services of digital forms of money.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S. Crypto Concept Stocks, ranked from highest to lowest based on real-time market data. Companies involved in the creation, trade, and services of digital forms of money.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S. Crypto Concept Stocks, ranked from highest to lowest based on real-time market data.
CervoMed Stock Forum
should have known to get out when I saw the comment
CervoMed Announces Topline Data from RewinD-LB Phase 2b Clinical Trial in Patients with Dementia with Lewy Bodies
Tuesday, 10th December at 7:00 am
—Neflamapimod did not demonstrate statistically significant effects versus placebo on primary and secondary endpoints at 16 weeks—
—Favorable safety and tolerability results with no new safety signal identified—
—Target plasma drug concentrations not achieved during 16-week double-blind phase of the trial—
—Trial participants ...
No comment yet